Literature DB >> 8098437

Secondary leukaemia after MMM combined modality therapy for breast carcinoma.

N J Philpott, D H Bevan, E C Gordon-Smith.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8098437     DOI： 10.1016/0140-6736(93)91199-v

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  2 in total

1.  Ethnic variation in the prevalence of a common NAD(P)H quinone oxidoreductase polymorphism and its implications for anti-cancer chemotherapy.

Authors:  K T Kelsey; D Ross; R D Traver; D C Christiani; Z F Zuo; M R Spitz; M Wang; X Xu; B K Lee; B S Schwartz; J K Wiencke
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

2.  Secondary myelodysplastic syndrome/acute myeloid leukaemia following mitoxantrone-based therapy for breast carcinoma.

Authors:  R Saso; S Kulkarni; P Mitchell; J Treleaven; G J Swansbury; J Mehta; R Powles; S Ashley; A Kuan; T Powles
Journal:  Br J Cancer       Date:  2000-07       Impact factor: 7.640
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.